(Q44744561)

5 December 2017

Infliximab therapy for sarcoidosis (lupus pernio). (English)

1 reference

5 December 2017

Haley H

1

1 reference

5 December 2017

Cantrell W

series ordinal

2

1 reference

5 December 2017

Smith K

series ordinal

3

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

British Journal of Dermatology

5 December 2017

1 reference

5 December 2017

150

1 reference

5 December 2017

1

1 reference

5 December 2017

146-149

1 reference

Infliximab decreases resource use among patients with Crohn's disease.

5 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Inflammatory status and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Drug-induced systemic lupus erythematosus associated with etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Etanercept and infliximab associated with cutaneous vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

Pneumocystis carinii pneumonia following a second infusion of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05769.X

10.1111/J.1365-2133.2004.05769.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference